Eiger Mountains

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Eiger Announces Breakthrough Therapy Designation Granted by FDA for Lonafarnib in Progeria and Progeroid Laminopathies
- Survival Benefit in Children with Progeria Published in JAMA 2018 - NDA Filing Planned in 2019 PALO ALTO, Calif. , Dec. 19, 2018 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare and ultra-rare diseases,
View HTML
Toggle Summary Eiger Announces PRIME Designation Granted by European Medicines Agency for Lonafarnib for Treatment of Hepatitis Delta Virus Infection
- Phase 3 HDV "D-LIVR" International Study Initiating PALO ALTO, Calif. , Dec. 18, 2018 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare and ultra-rare diseases, today announced the European Medicines
View HTML
Toggle Summary Eiger Announces Breakthrough Therapy Designation Granted by FDA for Lonafarnib for Treatment of Hepatitis Delta Virus (HDV) Infection
- Phase 3 HDV "D-LIVR" International Study Initiating PALO ALTO, Calif. , Dec. 17, 2018 /PRNewswire/ --   Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare and ultra-rare diseases, today announced that the Food and Drug
View HTML
Toggle Summary Eiger BioPharmaceuticals Reports on 2018 R&D Day
-- Late Stage Rare and Ultra-Rare Disease Pipeline Advancing -- >$100M in Cash Available to Achieve Key Milestones PALO ALTO, Calif. , Dec. 11, 2018 /PRNewswire/ --   Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare and
View HTML
Toggle Summary Eiger BioPharmaceuticals to Host R&D Day in New York City
PALO ALTO, Calif. , Dec. 4, 2018 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare and ultra-rare diseases, today announced it will host an R&D Day on December 11, 2018 from 12:00 PM to 2:30 PM EST at the
View HTML
Toggle Summary Eiger BioPharmaceuticals Announces the Appointment of Sri Ryali as Chief Financial Officer
PALO ALTO, Calif. , Dec. 3, 2018 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare and ultra-rare diseases, today announced the appointment of Sri Ryali as the company's Chief Financial Officer.  Mr.
View HTML
Toggle Summary Eiger BioPharmaceuticals Announces FDA Acceptance of IND Application for Lonafarnib for the Treatment of Progeria and Progeroid Laminopathies
- Plans to File NDA in 2019 PALO ALTO, Calif. , Dec. 3, 2018 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare and ultra-rare diseases, today announced that the U.S.
View HTML
Toggle Summary Eiger to Participate in Piper Jaffray Healthcare Conference
PALO ALTO, Calif. , Nov. 19, 2018 /PRNewswire/ --   Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, today announced that David Cory , President and CEO, will present a corporate update at the 30 th Annual Piper
View HTML
Toggle Summary Eiger Bio Reports Third Quarter 2018 Financial Results
- HDV Phase 3 D-LIVR study start in 2018 and Progeria NDA planned in 2019 - Over $100 million in cash to advance late stage rare disease pipeline PALO ALTO, Calif. , Nov. 9, 2018 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of
View HTML
Toggle Summary Eiger BioPharmaceuticals Prices Previously Announced Public Offering of Common Stock
PALO ALTO, Calif. , Oct. 23, 2018 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR), a clinical-stage biopharmaceutical company focused on the accelerated development and commercialization of targeted therapies for rare and ultra-rare diseases, announced today the pricing of its
View HTML
Toggle Summary Eiger BioPharmaceuticals Announces Proposed Public Offering of Common Stock
PALO ALTO, Calif. , Oct. 22, 2018 /PRNewswire/ --   Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR), focused on the development and commercialization of targeted therapies for rare diseases, today announced that it has commenced an underwritten public offering of its common stock.
View HTML
Toggle Summary Eiger BioPharmaceuticals Receives FDA Rare Pediatric Disease (RPD) Designation for Lonafarnib for the Treatment of Progeria and Progeroid Laminopathies and Plans NDA Filing in 2019
- Designation Enables Priority Review Voucher Eligibility Upon NDA Approval PALO ALTO, Calif. , Oct. 22, 2018 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare diseases, today announced that the U.S.
View HTML
Toggle Summary Eiger BioPharmaceuticals to Participate at BTIG Biotech Conference
PALO ALTO, Calif. , Oct. 18, 2018 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare diseases, today announced the Eiger management team will participate and host 1:1 investor meetings at the BTIG Biotech
View HTML
Toggle Summary Eiger BioPharmaceuticals Announces Positive Phase 2 LIMT Study End of Treatment Data with Pegylated Interferon Lambda Monotherapy in Hepatitis Delta Virus (HDV) Infection
- Lambda Antiviral Activity Demonstrated in HDV Infection - Currently Dosing Lambda in Combination with Lonafarnib in HDV Infection PALO ALTO, Calif. , Oct. 17, 2018 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. , (NASDAQ: EIGR) today announced positive data with Pegylated Interferon Lambda
View HTML
Toggle Summary Eiger BioPharmaceuticals Announces Positive Results in Phase 2 PREVENT Study of Avexitide Targeting GLP-1 in Post-Bariatric Hypoglycemia (PBH)
- Primary and Secondary Endpoints Achieved with Statistical Significance - Avexitide Treatment Reduces Hypoglycemia and Hyperinsulinism PALO ALTO, Calif. , Oct. 16, 2018 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted
View HTML
Toggle Summary Eiger BioPharmaceuticals Announces Phase 2 ULTRA Results of Ubenimex in Lower Leg Lymphedema: Study Did Not Meet Primary or Secondary Endpoint
PALO ALTO, Calif. , Oct. 16, 2018 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, today announced Phase 2 ULTRA study results in primary and secondary lymphedema of the lower limb demonstrated
View HTML
Toggle Summary Eiger BioPharmaceuticals to Participate in Investor Conferences
PALO ALTO, Calif. , Sept. 25, 2018 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare and ultra-rare diseases, today announced that David Cory , President and CEO, will present at two investor conferences in
View HTML
Toggle Summary Eiger Announces FDA Guidance on HDV Phase 3 Study Design: Primary Endpoint Established; D-LIVR Study Initiating Q4 2018
D-LIVR Study: First-Ever Registration Study for Chronic HDV Infection PALO ALTO, Calif. , Sept. 24, 2018 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, today announced the receipt of written
View HTML
Toggle Summary Eiger Announces Positive Meeting with FDA on Progeria Program
- Company advancing plans to file NDA for Lonafarnib in Progeria PALO ALTO, Calif. , Sept. 4, 2018 /PRNewswire/ -- Today,  Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR), a company focused on the development and commercialization of targeted therapies for rare diseases, announced it has received
View HTML
Toggle Summary Eiger BioPharmaceuticals to Participate in Investor Conferences
PALO ALTO, Calif. , Aug. 27, 2018 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today that members of the Eiger management team will participate in multiple investor conferences in
View HTML
Toggle Summary Eiger BioPharmaceuticals Announces Completion of Enrollment in Phase 2 PREVENT Study of Avexitide (formerly Exendin 9-39) in Patients Suffering from Post-Bariatric Hypoglycemia
PALO ALTO, Calif. , Aug. 13, 2018 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced completion of enrollment of the Phase 2 PREVENT study.  PREVENT is a multi-center, placebo-controlled
View HTML
Toggle Summary Eiger BioPharmaceuticals Reports Second Quarter 2018 Financial Results
PALO ALTO, Calif. , Aug. 10, 2018 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today financial results for the three and six months ended June 30, 2018 and provided a business
View HTML
Toggle Summary Eiger BioPharmaceuticals to Present at 2018 Wedbush PacGrow Healthcare Conference
PALO ALTO, Calif. , Aug. 7, 2018 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today that David Cory , President and CEO, will present a corporate update at the 2018 Wedbush PacGrow
View HTML
Toggle Summary Eiger BioPharmaceuticals Announces First Patient Enrolled in Phase 2 LIFT Study of Pegylated Interferon Lambda in Combination with Ritonavir-Boosted Lonafarnib at National Institutes of Health
PALO ALTO, Calif. , Aug. 6, 2018 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today first patient enrolled in the Phase 2 LIFT Study conducted within the National Institutes of
View HTML
Toggle Summary Eiger BioPharmaceuticals Announces Notice of Allowance for U.S. Patent Covering a Broad Range of Ritonavir-Boosted Lonafarnib Dosing Regimens for Treatment of Hepatitis Delta Virus Infection
PALO ALTO, Calif. , July 31, 2018 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today that it has received the Notice of Allowance from the United States Patent and Trademark Office
View HTML
Toggle Summary Eiger Announces HDV Phase 2 Program Oral Presentation and Investigator / Key Opinion Leader Reception for Planned HDV Phase 3 D-LIVR Study at Global Hepatitis Summit 2018™
PALO ALTO, Calif. , June 4, 2018 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today that an oral presentation from the Phase 2 LOWR HDV ( LO nafarnib W ith R itonavir in H epatitis
View HTML
Toggle Summary Eiger BioPharmaceuticals to Present at Jefferies 2018 Global Healthcare Conference
PALO ALTO, Calif. , May 30, 2018 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on bringing to market novel product candidates for the treatment of rare diseases, announced today that David Cory , President and CEO, will present a corporate update at Jefferies 2018 Global
View HTML
Toggle Summary Eiger BioPharmaceuticals Prices Previously Announced Public Offering of Common Stock
PALO ALTO, Calif. , May 24, 2018 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR), a clinical-stage biopharmaceutical company focused on bringing to market novel product candidates for the treatment of rare diseases, announced today the pricing of its previously announced underwritten
View HTML
Toggle Summary Eiger BioPharmaceuticals Announces Proposed Public Offering of Common Stock
PALO ALTO, Calif. , May 23, 2018 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR), a clinical-stage biopharmaceutical company focused on bringing to market novel product candidates for the treatment of rare diseases, announced today that it has commenced an underwritten public offering
View HTML
Toggle Summary Eiger Announces Expanded License Agreement with Merck for Investigational Candidate Lonafarnib and Collaboration with The Progeria Research Foundation (PRF)
- Plans to Seek FDA Guidance for Potential Hutchinson-Gilford Progeria Syndrome (HGPS or Progeria) Indication PALO ALTO, Calif. , May 16, 2018 /PRNewswire/ --   Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR), focused on the development and commercialization of targeted therapies for rare diseases,
View HTML
Toggle Summary Eiger BioPharmaceuticals Reports First Quarter 2018 Financial Results
- Hepatitis Delta Virus (HDV) Program Moving into Phase 3 - Phase 2 Clinical Results Planned Across All Pipeline Programs in Second Half 2018 - Existing Cash Runway Extends Through Mid-2019 PALO ALTO, Calif. , May 11, 2018 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc.
View HTML
Toggle Summary Eiger Announces Sub-Analysis of Phase 2 Results Demonstrating High Response Rates to "All-Oral" Lonafarnib-Ritonavir Regimen in Low Viral Load HDV-Infected Patients at The International Liver Congress™ 2018
PALO ALTO, Calif. , April 17, 2018 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc., (NASDAQ: EIGR) today announced additional positive lonafarnib (LNF) data from the LOWR HDV ( LO nafarnib W ith R itonavir in H epatitis D elta V irus) Program presented at The International Liver Congress™ 2018, in
View HTML
Toggle Summary Eiger BioPharmaceuticals to Participate in Conferences in April
PALO ALTO, Calif. , April 2, 2018 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today that Eiger will participate at upcoming investor, scientific, and orphan drug conferences in
View HTML
Toggle Summary Eiger Announces First Patient Dosed in Phase 2 PREVENT Study of Exendin 9-39 in Patients Suffering from Post-Bariatric Hypoglycemia
PALO ALTO, Calif. , March 26, 2018 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of therapies for rare diseases, today announced the first patient dosed in PREVENT, a Phase 2, multi-center study of subcutaneous (SC) exendin 9-39 in
View HTML
Toggle Summary Eiger BioPharmaceuticals Announces Positive Guidance Following FDA Meeting on Hepatitis Delta Virus Registration Program
- Phase 3 D-LIVR Trial Planned to Initiate in Second Half 2018 PALO ALTO, Calif. , March 21, 2018 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today positive FDA guidance from a
View HTML
Toggle Summary Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results
- Hepatitis Delta Virus Program Moving into Phase 3 in 2018 - Phase 2 Clinical Results Planned from Three Pipeline Programs in 2018 - Cash Runway Extends Through Mid-2019 PALO ALTO, Calif. , March 12, 2018 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc.
View HTML
Toggle Summary Eiger BioPharmaceuticals to Participate in U.S. and International Investor and Partnership Conferences in March
PALO ALTO, Calif. , March 6, 2018 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today that David Cory , President and CEO of Eiger, will present a corporate overview and business
View HTML
Toggle Summary Eiger Announces Abstracts and Presentations of LOWR HDV Program and Planned Registration Program at The International Liver Congress™ Meeting
PALO ALTO, Calif. , March 5, 2018 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc., (NASDAQ: EIGR) today announced that abstracts from its LOWR HDV ( LO nafarnib W ith R itonavir in H epatitis D elta V irus) Program will be presented at The International Liver Congress™ meeting in Paris, France ,
View HTML
Toggle Summary Eiger BioPharmaceuticals to Participate in Two Upcoming Investor Conferences in February
PALO ALTO, Calif. , Feb. 6, 2018 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today that David Cory , President and CEO of Eiger, will present a corporate overview and business
View HTML
Toggle Summary Eiger BioPharmaceuticals Announces Phase 2 LIBERTY Study in Pulmonary Arterial Hypertension Did Not Meet Primary Endpoint
- End of Phase 2 Meeting Scheduled for HDV in February 2018 - Phase 2 Readouts for PBH and Lymphedema in Second Half 2018 PALO ALTO, Calif. , Jan. 16, 2018 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare
View HTML
Toggle Summary Eiger BioPharmaceuticals Announces Appointment of Commercial Operations Industry Veteran Eldon Mayer to its Board of Directors
PALO ALTO, Calif. , Jan. 8, 2018 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of therapies for rare diseases, announced today the appointment of Eldon Mayer to its Board of Directors.  Mr.
View HTML
Toggle Summary Eiger BioPharmaceuticals Completes Enrollment of Phase 2 ULTRA Study of Ubenimex in Primary and Secondary Lymphedema Patients
- ULTRA Study Data Expected in Second Half 2018 PALO ALTO, Calif. , Jan. 4, 2018 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced completion of enrollment of the Phase 2 ULTRA study. 
View HTML
Toggle Summary Eiger BioPharmaceuticals Appoints David Apelian, MD, PhD, MBA Chief Operating Officer and Executive Medical Officer
PALO ALTO, Calif. , Jan. 3, 2018 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of therapies for rare diseases, announced today the appointment of David Apelian , MD, PhD, MBA as Chief Operating Officer and Executive Medical Officer.
View HTML
Toggle Summary Eiger BioPharmaceuticals to Present at Biotech Showcase™ 2018
PALO ALTO, Calif. , Jan. 2, 2018 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for orphan diseases, announced today that David Cory , President and CEO, will present a corporate update at Biotech Showcase ™
View HTML